Oct 1, 2011
By:
David Balekdjian
Robert Seidman, Former Chief Pharmacy Officer, Wellpoint
|
|
The notion that employers would continue to pay the cost, whatever it was, has been turned on its ear.
Jan 1, 2005
By:
Michael Russo, David Balekdjian
Citing cherry-picked patients, unrealistic dosing, and placebo control, payers will increasingly require that the proof for payment of drugs must come from head-to-head trials.
|
|
A new study says biologics are at the top of payers' lists for cost containment efforts.
Jun 1, 2004
By:
David Balekdjian, Michael Russo
Biologics and specialty pharmaceuticals, which typically target small patient populations, have historically necessitated a high per-patient cost to justify their R&D investment and expensive manufacturing and packaging processes.
|
A new survey reveals what MCOs and PBms really want: Products with value-and the clinical proof that demonstrates Their Worth.
Sep 1, 2003
By:
David Balekdjian, Michael Russo
Affordable healthcare has become a leading political and social hot button in the United States, and managed care organizations (MCOs) have responded by seeking to reduce pharmaceutical expenses to rein in rapidly increasing costs.
|
New guidelines for formulary submissions Redefine the value of pharma products.
Nov 1, 2002
By:
David Balekdjian, Michael Russo
Managed care organizations (MCOs) and pharmacy benefit managers (PBMs)-representing 110 million US patients-have adopted new guidelines for formulary submissions. As a result, they now reject 40 percent of new drugs. Those standards, the most visible component in an approach called outcomes-based access, indicate a revolutionary change in the formulary decision making process that affects 46 percent of the insured population. Many pharmaceutical companies are being caught by surprise.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
